{'fraction_non_alphanumeric': 0.012776831345826235, 'fraction_numerical': 0.0034071550255536627, 'mean_word_length': 5.752873563218391, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A Review: Influenza and its Therapeutic Approaches

The high degree of variability amongst influenza viruses is the main characteristic that provides the greatest challenge to development of prophylactic and therapeutic solutions against epidemic and pandemic outbreaks. Therapeutic treatment option for pandemic, seasonal and zoonotic influenza viruses are antiviral neuraminidase inhibitors. Currently neuraminidase inhibitors, such as oseltamivir, zanamivir, laninamivir, and peramivir can be used as potential drug use for treatment for H1N1 in different countries 1, 2 but due to some controversies and emerging in resistance the effectiveness of such drug decreases. In this review article we focus on different aspects for treatment such as Monoclonal antibody, Sialic acid inhibitor and universal influenza vaccine. In the past decade, more focus will be on universal influenza vaccine for treatment which provides the long lasting effect on multiple subtype of flu rather than particular type of flu, such vaccine can provide the protection against seasonal and newly emerging flu viruses and based on relatively conserved sequence and protein of influenza viruses.